Saiyuri Naicker

Saiyuri Naicker

Auto-generated profile, based on publicly available information

Saiyuri Naicker

UQ Centre for Clinical Research, Faculty of Health, Medicine and Behavioural Sciences, University of Queensland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
SNSaiyuri Naicker
Saiyuri Naicker
YVYarmarly C. Guerra Valero
Yarmarly C. Guerra Valero
JMJenny L. Ordenez Meija
Jenny L. Ordenez Meija
Jeffrey LipmanJeffrey Lipman
Jeffrey Lipman
JRJason Roberts
Jason Roberts
SPSuzanne L Parker
Suzanne L Parker

1 July 2016 in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
Verified
Journal Article
Closed access
PDF file
DRDwarakanathan Ranganathan
Dwarakanathan Ranganathan
SNSaiyuri Naicker
Saiyuri Naicker
SWSteven C. Wallis
Steven C. Wallis
Jeffrey LipmanJeffrey Lipman
Jeffrey Lipman
SRSharad K. Ratanjee
Sharad K. Ratanjee
JRJason Roberts
Jason Roberts
Background and objectives: Patients with peritoneal dialysis (PD)-associated peritonitis may be advised to store PD-bags with pre-mixed antibiotics at home, although there is a paucity of antibiotic stability studies in the commonly used icodextrin solutions. The purpose of this study was to assess the stability of various antibiotics in PD-bags when stored at different temperatures over a 14-day period. Methods: 7.5% icodextrin PD-bags were dosed with gentamicin 20 mg/L ( n = 9), vancomycin 1,000 mg/L ( n = 9), cefazolin 500 mg/L ( n = 9) and ceftazidime 500 mg/L ( n = 9) as for intermittent dosing. Combinations of gentamicin/vancomycin ( n = 9), cefazolin/ceftazidime ( n = 9), and cefazolin/gentamicin ( n = 9) were also tested. Nine drug-free bags were used as controls. Bags were stored in triplicate at 37°C, room-temperature (25°C), and refrigeration (4°C). Antibiotic concentrations were quantified at various time intervals using validated chromatography. Storage duration was considered unstable if the concentration of the antibiotic dropped ≤ 90% of the initial value. Results: Gentamicin was stable for 14 days at all temperatures. Vancomycin was stable for 4 days at 37°C and for 14 days at both 25°C and 4°C. The gentamicin and vancomycin combination was stable for 4 days at 37°C and for 14 days at 25°C and 4°C. Cefazolin alone was stable for 24 hours at 37°C, 7 days at 25°C, and 14 days at 4°C. Ceftazidime alone was stable for only 6 hours at 37°C, 2 days at 25°C, and 14 days at 4°C. The cefazolin and ceftazidime combination was stable for 24 hours at 37°C, 2 days at 25°C, and 14 days at 4°C. The cefazolin and gentamicin combination was stable for 1 day at 37°C, 4 days at 25°C, and 14 days at 4°C. Conclusions: Antibiotics premixed in icodextrin PD-bags have varying stabilities with stability generally least at 37°C and best at 4oC, permitting storage for 14 days when refrigerated and pre-warming to body temperature prior to administration. Further research confirming the sterility of these antibiotic-containing bags is recommended.

9 November 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
SLSazlyna Mohd Sazlly Lim
Sazlyna Mohd Sazlly Lim
AHAaron Heffernan
Aaron Heffernan
SNSaiyuri Naicker
Saiyuri Naicker
SWSteven Wallis
Steven Wallis
JRJason Roberts
Jason Roberts
FSFekade Sime
Fekade Sime
Static concentration in vitro studies have demonstrated that fosfomycin- or sulbactam-based combinations may be efficacious against carbapenem-resistant Acinetobacter baumannii (CRAB). In the present study, we aimed to evaluate the bacterial killing and resistance suppression potential of fosfomycin-sulbactam combination therapies against CRAB isolates in a dynamic infection model. We simulated clinically relevant dosing regimens of fosfomycin (8 g every 8 h, 1 h infusion) and sulbactam (12 g continuous infusion or 4 g every 8 h, 4 h infusion) alone and in combination for 7 days in a hollow-fibre infection model (HFIM) against three clinical isolates of CRAB. The simulated pharmacokinetic profiles in the HFIM were based on fosfomycin and sulbactam data from critically ill patients. Fosfomycin monotherapy resulted in limited bacterial killing. Sulbactam monotherapies resulted in ~ 3 to 4 log10 kill within the first 8 to 32 h followed by regrowth of up to 8 to 10 log10 CFU/mL. A combination of fosfomycin and continuous infusion of sulbactam led to a ~2 to 4 log10 reduction in bacterial burden within the first 24 h, which was sustained throughout the duration of the experiments. A combination of fosfomycin and extended infusion of sulbactam produced a ~4 log10 reduction in colony count within 24 h. This study demonstrated that fosfomycin in combination with sulbactam is a promising option for the treatment of MDR A. baumannii. Further studies are needed to further assess the potential clinical utility of this combination.

1 October 2020 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
SLS. Mohd Sazlly Lim
S. Mohd Sazlly Lim
SNS. Naicker
S. Naicker
AAA.K. Ayfan
A.K. Ayfan
HZH. Zowawi
H. Zowawi
JRJ.A. Roberts
J.A. Roberts
FSFekade Sime
Fekade Sime

19 September 2023 in Journal of Periodontology
Verified
Journal Article
Open access
SRSrinivas Sulugodu Ramachandra
Srinivas Sulugodu Ramachandra
FSFekade Sime
Fekade Sime
SNSaiyuri Naicker
Saiyuri Naicker
Pingping HanPingping Han
Pingping Han
RLRyan Lee
Ryan Lee
Saso IvanovskiSaso Ivanovski
Saso Ivanovski
Background: The aim of this study was to investigate an in vitro dynamic bioreactor model by evaluating the antimicrobial effect of clinically relevant amoxicillin doses on polymicrobial microcosm biofilms derived from subgingival plaque.Methods: Biofilms from pooled subgingival plaque were grown for 108 hours in control and experimental dynamic biofilm reactors. Amoxicillin was subsequently infused into the experimental reactor to simulate the pharmacokinetic profile of a standard 500 mg thrice‐daily dosing regimen over 5 days and biofilms were assessed by live/dead staining, scanning electron microscopy, and quantitative polymerase chain reaction.Results: Following establishment of the oral microcosm biofilms, confocal imaging analysis showed a significant increase in dead bacteria at 8 hours (p = 0.0095), 48 hours (p = 0.0070), 96 hours (p = 0.0140), and 120 hours (p < 0.0001) in the amoxicillin‐treated biofilms compared to the control biofilms. Nevertheless, viable bacteria remained in the center of the biofilm at all timepoints. Significant reductions/elimination in Campylobacter rectus, Tannerella forsythia, Aggregatibacter actinomycetemcomitans, and Peptostreptococcus anaerobius was observed among the amoxicillin‐treated biofilms at the 96 and 120 hour timepoints.Conclusion: A novel in vitro dynamic model of oral microcosm biofilms was effective in modeling the antimicrobial effect of a pharmacokinetically simulated clinically relevant dose of amoxicillin.

30 October 2024 in JAC-Antimicrobial Resistance
Verified
Journal Article
Open access
SNSaiyuri Naicker
Saiyuri Naicker
JRJason Roberts
Jason Roberts
VCVesa Cheng
Vesa Cheng
SPSuzanne L Parker
Suzanne L Parker
RSR Andrew Seaton
R Andrew Seaton
FSFekade Sime
Fekade Sime
Antimicrobial stability is an important consideration for treatment planning and service delivery in outpatient parenteral antimicrobial therapy (OPAT) programmes. Regulation of stability assessment varies by region, and conflicting guidance and standards exist. This leads to disparity of equity in access and limits availability of certain antimicrobials for managing infections in the outpatient setting. This review discusses the degree to which the international regulatory bodies have reached consensus on the regulation of antimicrobial stability testing, specifically for OPAT, and describes the variation in antimicrobial recommendations across regulatory bodies. The three major findings in this review are (i) variation in antimicrobial stability testing guidance, particularly in relation to temperature; (ii) lack of regulatory guidance, specifically in that some regions did not have OPAT guidelines; and (iii) only the UK’s NHS has provided non-regulatory OPAT-specific advice on antimicrobial stability testing. In conclusion, harmonization of antimicrobial stability testing to form a global OPAT-specific regulatory framework, particularly considering ‘areas of variation’ amongst current guidance, is required. We call for the development of a global OPAT antimicrobial stability testing framework with consensus from accepted antimicrobial stability criteria, expert opinion and pharmacopoeial best practice.